Main Article Content


COVID-19 are an unprecedented challenge for healthcare providers; there are no approved treatments for this disease, nor are there no approved vaccines. The sources of infection of novel coronavirus detected mainly from animals to humans or infected human to healthy human through respiratory droplets and long contact period are the most prominent way of transmission. Coronaviruses are structurally large-sized single-stranded RNA viruses. The capability of regular therapies is constantly fading away exactly in case of coronavirus due to the modiϑication of new strain, which could be certainly due to speedy adaptation in a protein sequence. The scientist should understand the pandemic situation of virus infection, also as they ought to identify the newest pathway research to regulate the virus infection. Developing new and smart strategies for drugs already in the development pipeline or already exiting drug can be treating diseases in patients could be useful to ϑight against COVID-19. In the last few years, several new smart drug delivery approaches made the changeover from the laboratory development to clinical applications. At present technology, researchers provide effective and low toxicity drug delivery when compared with classical delivery. This approach will be a great opportunity for the scientist to work and update preclinical research of advance drug delivery systems to cloneable and convertible production to the human trial success rate. In conclusion, by understanding the new drug delivery research approaches for antiviral therapy are increases to produce safe and high-quality therapies at reasonable costs.


Smart drug delivery approach Covid-19 Infection Nano-based antiviral therapy virus killer

Article Details

How to Cite
Sudhakar Kothandan, Aravindhanathan Venkatesan, Arun Radhakrishnan, Karri VVS Narayanan Reddy, Gowthamarajan Kuppusamy, Dhanabal S. P., Somanathan Balasubramanian, & Suresh Bhojraj. (2020). Bite-sized Review on Advance Delivery System, Support in the management of Covid-19. International Journal of Research in Pharmaceutical Sciences, 11(SPL1), 158-164.

Most read articles by the same author(s)